Details of the Drug Combinations

General Information of This Drug (ID: DMES906)

• Drug Name: 3,7,3',4'-TETRAHYDROXYFLAVONE (DMES906)
• Synonyms: Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN

Indication

Discovery agent; ICD 11: N.A.; Status: Investigative [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
3,7,3',4'-TETRAHYDROXYFLAVONE + Idarubicin	DC2X0PS	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
3,7,3',4'-TETRAHYDROXYFLAVONE + Losartan	DCI7PS8	Losartan	Osteoarthritis, Knee	[3]

References

• [1] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT04815902) Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis